SCHEMBL10154055

SCHEMBL10154055

CNC(=O)c1cccc(N2CCCCC2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.64
KMT2A Q03164 4/20 0.64
ALDH1A1 P00352 3/20 0.64
KDM4E B2RXH2 1/20 0.64
GAA P10253 1/20 0.64
HPGD P15428 1/20 0.64
HSD17B10 Q99714 1/20 0.64
MLYCD O95822 1/20 0.52
HDAC8 Q9BY41 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
PRMT6 Q96LA8 1/20 0.51
L3MBTL1 Q9Y468 3/20 0.51
L3MBTL3 Q96JM7 2/20 0.51
MAPT P10636 6/20 0.50
NPC1 O15118 6/20 0.50
RAB9A P51151 6/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
TSHR P16473 2/20 0.50
TP53 P04637 2/20 0.50
PKM P14618 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13702428 0.98 MEN1 (0.66) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL13247636 0.86 PLOD2 (0.60) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL4437239 0.85 KMO (0.68) MEN1KMT2AALDH1A1MLYCDHDAC6
SCHEMBL6263784 0.85 KAT6A (0.60) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL13702156 0.85 MEN1 (0.60) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL18826498 0.84 MEN1 (0.57) MEN1KMT2AALDH1A1KDM4EGAA
Hydrochloric Acid SCHEMBL6413194 0.84 KAT6A (0.59) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL27694996 0.84 MEN1 (0.54) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL13701687 0.84 MEN1 (0.59) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL13702169 0.83 MEN1 (0.62) MEN1KMT2AALDH1A1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165309-A1 HETERO RING DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-28 US disclosed
EP-2397479-A1 HETERO RING DERIVATIVE Astellas Pharma Inc. (JP) 2011-12-21 EP disclosed
WO-2010092962-A1 HETERO RING DERIVATIVE アステラス製薬株式会社 (JP) 2010-08-19 WO disclosed
WO-2007067836-A2 SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165309-A1 HETERO RING DERIVATIVE IL2, PIK3R2, IL2RA MEN1 4630/4885KMT2A 1656/4885ALDH1A1 3496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.